<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute phase reactants</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute phase reactants</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute phase reactants</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Irving Kushner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Antonelli, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel E Furst, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An increase in the concentration of serum proteins that are referred to as acute phase reactants (APR) accompanies inflammation [<a href="#rid1">1,2</a>]. Awareness of this phenomenon, termed the acute phase response, first occurred with the discovery of C-reactive protein (CRP) in the serum of patients during the acute phase of pneumococcal pneumonia [<a href="#rid3">3,4</a>]. During the acute phase response, the usual levels of plasma proteins ordinarily maintained by homeostatic mechanisms can change significantly. These changes are thought to contribute to host defense and other adaptive capabilities.</p><p>A discussion of the biology of the acute phase response; the general clinical utility and interpretation of measurement of APR, such as CRP; and the clinical utility of indirect measures of the acute phase response, such as the erythrocyte sedimentation rate (ESR), are presented here. Detailed reviews of disorders associated with variations in APR and the utility of APR measurements in specific conditions, the innate immune response, and the role of cytokines in immunity and inflammation are described separately (see appropriate topic reviews of individual clinical disorders). (See  <a class="medical medical_review" href="/d/html/13572.html" rel="external">"An overview of the innate immune system"</a> and  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p class="headingAnchor" id="H56057146"><span class="h1">THE ACUTE PHASE RESPONSE</span></p><p class="headingAnchor" id="H56057153"><span class="h2">Definition and regulation</span><span class="headingEndMark"> — </span>Despite its name, the acute phase response accompanies chronic as well as acute inflammatory states and is associated with a wide variety of disorders, including infection, trauma, infarction, inflammatory arthritides, other systemic autoimmune and inflammatory diseases, and various neoplasms. Less marked changes may occur in response to metabolic stresses [<a href="#rid5">5</a>]. Acute phase proteins are defined as those proteins whose serum concentrations increase or decrease by at least 25 percent during inflammatory states [<a href="#rid1">1</a>]. Such proteins are termed either positive or negative acute phase reactants (APR), respectively. The erythrocyte sedimentation rate (ESR), an indirect APR, reflects plasma viscosity and the presence of acute phase proteins, especially fibrinogen, as well as other influences, some of which are as yet unidentified [<a href="#rid6">6</a>]. (See <a class="local">'Erythrocyte sedimentation rate'</a> below.)</p><p>Changes in the levels of APR largely reflect altered production by hepatocytes, resulting primarily from the effects of cytokines produced during the inflammatory process by macrophages, monocytes, and a variety of other cells. Interleukin (IL) 6 is the major inducer of most APR [<a href="#rid7">7</a>]. Some of the other major cytokines relevant to the acute phase response are IL-1 beta, tumor necrosis factor (TNF)-alpha, and interferon gamma. These cytokines also suppress the synthesis of albumin, termed a "negative APR" because its levels decrease with inflammation [<a href="#rid8">8</a>]. Combinations of cytokines can have additive, inhibitory, or synergistic effects, and patterns of cytokine production differ under various inflammatory conditions [<a href="#rid9">9-11</a>]. (See  <a class="medical medical_review" href="/d/html/129345.html" rel="external">"Interleukin 6 inhibitors: Biology, principles of use, and adverse effects"</a> and  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a> and  <a class="medical medical_review" href="/d/html/7513.html" rel="external">"Pathogenesis of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/4669.html" rel="external">"Epidemiology and pathogenesis of systemic lupus erythematosus"</a> and  <a class="medical medical_review" href="/d/html/7554.html" rel="external">"Pathogenesis of systemic sclerosis (scleroderma)"</a>.)</p><p>Increases in APR can vary from approximately 50 percent for ceruloplasmin and several components of the complement cascade to 1000-fold or more for C-reactive protein (CRP) and serum amyloid A (SAA). Additional positive APR include fibrinogen, levels of which have substantial effects on the ESR; alpha-1 antitrypsin; haptoglobin; IL-1 receptor antagonist; hepcidin; ferritin; procalcitonin; and others [<a href="#rid9">9,12,13</a>]. Negative APR include albumin, transferrin, and transthyretin.</p><p>Molecules other than proteins may also exhibit acute phase behavior. Thus, during the acute phase response, concentrations of zinc and iron decrease, while concentrations of copper rise. The concentrations of a variety of vitamins also manifest acute phase behavior. This has been problematic for clinicians since the acute phase behavior of these molecules tends to be overlooked. As an example, it may be concluded erroneously that an individual is iron deficient when low serum iron levels are found but result from iron merely behaving as a negative APR. Similarly, vitamin D is a negative APR. Numerous metabolic stresses have been associated with low levels, and likewise, inflammatory insults, such as surgery, have been shown to lower vitamin D levels acutely [<a href="#rid14">14-21</a>]. This may in part explain why vitamin D supplementation has been a focus of numerous nutraceutical trials for coronavirus disease 2019 (COVID-19) [<a href="#rid22">22</a>], as well as cancer and cardiovascular disease [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H56057160"><span class="h2">Function</span><span class="headingEndMark"> — </span>The assumption that APR are largely beneficial is based on the known functions of the individual proteins but is also influenced by speculation as to how they may serve useful purposes in inflammation, healing, or adaptation to noxious stimuli. Inflammation is a complex, highly orchestrated process that involves many cell types and molecules which may initiate, amplify, sustain, attenuate, or abolish inflammation. A number of the participating molecules are also multifunctional, contributing to both the waxing and the waning of inflammation at different points in time [<a href="#rid24">24</a>]. (See <a class="local">'Roles of CRP'</a> below and <a class="local">'Roles of other proteins'</a> below.)</p><p>In addition to changes in plasma proteins, a number of physiologic, biochemical, behavioral, and nutritional changes are induced during the acute phase response by inflammation-associated cytokines. In addition to fever [<a href="#rid25">25,26</a>] and the development of anemia of chronic disease (also termed anemia of chronic inflammation) [<a href="#rid27">27</a>], the response can be associated with behavioral changes, such as anorexia, somnolence, and lethargy [<a href="#rid28">28,29</a>]; neuroendocrine effects, such as increased production of corticotropin-releasing hormone [<a href="#rid30">30</a>]; muscle wasting [<a href="#rid31">31-33</a>]; cachexia; impaired growth in children; altered serum concentrations of various cations, including iron, copper, and zinc; and secondary (AA or reactive) amyloidosis. Cytokine overproduction and imbalance can be fatal, as in septic shock [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a> and  <a class="medical medical_review" href="/d/html/1597.html" rel="external">"Pathophysiology of sepsis"</a>.)</p><p class="headingAnchor" id="H55783368"><span class="h3">Roles of CRP</span><span class="headingEndMark"> — </span>CRP and many other APR can influence multiple stages of inflammation, and CRP has both proinflammatory and antiinflammatory actions, although the primary effect may be antiinflammatory [<a href="#rid35">35,36</a>]. CRP can promote the recognition and elimination of pathogens and enhance the clearance of necrotic and apoptotic cells [<a href="#rid37">37-43</a>]. The protein consists of five identical, non-covalently associated subunits, each with a molecular weight of approximately 23 kD, which are arranged symmetrically around a central pore [<a href="#rid44">44</a>]. CRP and related proteins with this structure are termed pentraxins, which are a family of pattern recognition molecules involved in the innate immune response; others include serum amyloid P and a number of pattern recognition molecules referred to as long pentraxins [<a href="#rid45">45,46</a>]. (See  <a class="medical medical_review" href="/d/html/13572.html" rel="external">"An overview of the innate immune system", section on 'Pentraxins'</a>.)</p><p>A major function of CRP is its ability to bind phosphocholine, thereby permitting recognition both of foreign pathogens that display this moiety and phospholipid constituents of damaged cells [<a href="#rid37">37</a>]. CRP can also activate the complement system and bind to phagocytic cells via Fc receptors, suggesting that it can initiate elimination of pathogens and targeted cells by interaction with both humoral and cellular effector systems of inflammation [<a href="#rid36">36</a>]. These functions of CRP may have negative effects in some settings. As an example, CRP levels are increased in patients with immune thrombocytopenia (ITP), where CRP may amplify antibody-mediated platelet destruction upon binding to phosphocholine that is exposed after oxidation triggered by antiplatelet antibodies [<a href="#rid47">47</a>].</p><p>Proinflammatory effects of CRP include activation of the complement system and the induction in monocytes of inflammatory cytokines and tissue factor [<a href="#rid48">48,49</a>] and shedding of the IL-6 receptor [<a href="#rid50">50</a>]. As a result, the CRP response to tissue injury may worsen tissue damage in some settings [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H55783889"><span class="h3">Roles of other proteins</span><span class="headingEndMark"> — </span>Like CRP, other APR have a wide variety of functional effects, including initiating or sustaining inflammation, antiinflammatory effects, and effects on wound healing, as well as other functional consequences. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>The SAA proteins, a major human acute phase protein family, are apolipoproteins that are rapidly associated with high-density lipoprotein following their synthesis and secretion and can influence cholesterol metabolism during inflammatory states [<a href="#rid52">52,53</a>]. SAA may increase the adhesion and chemotaxis of phagocytic cells and lymphocytes [<a href="#rid54">54,55</a>]. However, in some patients with chronic inflammation, the net effect of increased SAA production is deleterious, because of the tissue deposition of SAA fragments and development of systemic amyloidosis. (See  <a class="medical medical_review" href="/d/html/5619.html" rel="external">"Pathogenesis of AA amyloidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complement components serve proinflammatory roles, including chemotaxis, plasma protein exudation at sites of inflammation, and opsonization of infectious agents and damaged cells. (See  <a class="medical medical_review" href="/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Haptoglobin and hemopexin are antioxidants that protect against reactive oxygen species by removing iron-containing cell-free hemoglobin and heme, respectively, from the circulation [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alpha-1 antitrypsin, which inhibits superoxide anion generation, and alpha-1-antichymotrypsin both antagonize proteolytic enzyme activity [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepcidin, a protein made by the liver, can contribute to decreases in serum iron by reducing intestinal iron absorption and impairing the release of iron from macrophages [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation", section on 'Hepcidin (primary regulator of iron homeostasis)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrinogen and haptoglobin influence wound healing. Fibrinogen causes endothelial cell adhesion, spreading, and proliferation, which are critical to tissue repair; and haptoglobin aids in wound repair by stimulating angiogenesis [<a href="#rid59">59</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL USE</span><span class="headingEndMark"> — </span>The measurement of serum acute phase reactant (APR) levels is useful because abnormalities generally reflect the presence and intensity of an inflammatory process. However, APR measurements in clinical use are not specific to any particular disease, nor can they distinguish infection from other causes of acute and chronic inflammation. The most widely used indicators of the acute phase response are the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels. (See <a class="local">'Erythrocyte sedimentation rate'</a> below and <a class="local">'C-reactive protein'</a> below and <a class="local">'Discrepancies between acute phase reactant levels'</a> below.)</p><p>In certain circumstances, the results of ESR and CRP determinations may be discrepant, sometimes strikingly so. This can occur due to factors related to the inflammatory process, including differences between APR in their sensitivity to change due to differences in the specific cytokines or their modulators in different diseases. However, discrepancies between the ESR and another APR can also result from factors that may increase or reduce the ESR but are unrelated to acute or chronic inflammation. (See <a class="local">'Discrepancies between acute phase reactant levels'</a> below and <a class="local">'Erythrocyte sedimentation rate'</a> below.)</p><p>Serum amyloid A (SAA) concentrations usually parallel those of CRP. Although some studies suggest that SAA is a more sensitive marker of inflammatory disease, assays for SAA are not widely available for use in routine clinical practice [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Erythrocyte sedimentation rate</span><span class="headingEndMark"> — </span>The ESR, defined as the rate (expressed in mm/hour) at which erythrocytes suspended in plasma fall when placed in a vertical tube, is an indirect measure of the acute phase response and of levels of APR, particularly fibrinogen [<a href="#rid6">6</a>]. It can be influenced by other constituents of the blood, such as immunoglobulins, as well. The ESR can also be affected by changes that may be unrelated to inflammation, including changes in erythrocyte size, shape, and number; and by other technical factors. (See <a class="local">'Increased ESR'</a> below and <a class="local">'Decreased ESR'</a> below.)</p><p class="headingAnchor" id="H58563664"><span class="h3">Increased ESR</span><span class="headingEndMark"> — </span>The ESR, like other APR, is increased in patients with active inflammation from most causes. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic and localized inflammatory and infectious diseases</p><p class="bulletIndent1"><span class="glyph">●</span>Malignant neoplasms</p><p class="bulletIndent1"><span class="glyph">●</span>Tissue injury/ischemia</p><p class="bulletIndent1"><span class="glyph">●</span>Trauma</p><p></p><p>Marked elevations in the ESR are more often due to infection than other causes, but noninfectious disorders are also a common etiology. In a retrospective study of 1006 consecutive outpatients, ESR values of over 100 mm/hour were most commonly due to infection (33 percent), with malignant neoplasms and renal disease responsible for 17 percent each and a variety of inflammatory disorders responsible for 14 percent [<a href="#rid61">61</a>].</p><p>Conditions or factors unrelated to acute or chronic inflammation that may also increase the ESR include:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased age and female sex – ESR values increase markedly with age [<a href="#rid62">62</a>] and are slightly higher among women than men. As a result, any single set of normal values will not be valid for the population at large. One can roughly correct ESR for age by using the following formulas: the upper limit of the reference range equals (age in years)/2 for men and (age in years + 10)/2 for women [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia – It has long been known that anemia increases the sedimentation rate [<a href="#rid64">64</a>]. The sedimentation of red blood cells is presumably impeded by other red blood cells; sedimentation is thus more rapid in anemia, in which this retardation is lessened, thus increasing the ESR. Macrocytosis may also increase ESR [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy – The pregnant state includes hemodilution because of increase in plasma volume; corrected for this anemia, ESR increases with gestational age of the pregnancy [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal disease – The ESR is elevated (greater than 25 mm/hour by the Westergren method) in almost all patients with end-stage kidney disease (ESKD) or the nephrotic syndrome, and is unaffected by hemodialysis [<a href="#rid67">67-69</a>]. Nearly 60 percent of patients with ESKD have an ESR above 60 mm/hour, while 20 percent have extreme elevations above 100 mm/hour. Thus, an isolated ESR elevation in a patient with renal disease, without other systemic signs or symptoms, does not necessarily indicate the presence of infection, disease activity, or an underlying malignancy (see  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology"</a>). Compared with hemodialysis patients, patients utilizing peritoneal dialysis have a higher ESR [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1">In one study of patients with glomerular disease, a positive correlation between the degree of proteinuria and the ESR was observed, with the ESR being found to be about 10 times the daily rate of protein excretion in patients who had not been treated with immunosuppressive agents [<a href="#rid71">71</a>]. The precise mechanism by which this occurs is not known, although an underlying inflammatory renal disease process may cause both an elevated ESR and result in proteinuria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obesity – Both ESR and CRP can be elevated in obesity [<a href="#rid72">72</a>]; this is due at least in part to interleukin (IL) 6 secretion by adipose tissue [<a href="#rid73">73</a>]. In fact, metabolic syndrome is associated with an increase in ESR [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other lifestyle characteristics – Smoking has been associated with elevated ESR [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Technical factors – Tilting of the ESR tube or high room temperature may increase the ESR.</p><p></p><p class="headingAnchor" id="H58564159"><span class="h3">Decreased ESR</span><span class="headingEndMark"> — </span>A number of factors may spuriously result in a very low ESR or ESR that is less than the expected level in a patient with acute or chronic inflammation [<a href="#rid75">75,76</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities of erythrocytes – Changes in red cell shape or number may reduce the ESR, including sickle cell disease, anisocytosis, spherocytosis, and acanthocytosis, as well as microcytosis and polycythemia. This can be confusing, for example, for patients with sickle cell disease, who may have a spuriously low ESR [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extreme leukocytosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extremely high serum bile salt levels [<a href="#rid76">76</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypofibrinogenemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cachexia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other lifestyle characteristics – Moderate and high regular physical activity has been associated with decreased ESR, as has light alcohol consumption (ie, one to four drinks weekly) compared with nonconsumers [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Technical factors, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clotting of the blood sample or delay in testing of greater than two hours</p><p class="bulletIndent2"><span class="glyph">•</span>Low room temperature</p><p class="bulletIndent2"><span class="glyph">•</span>Short ESR tube</p><p></p><p>Because low levels of fibrinogen are part of the macrophage activation syndrome (also known as acquired hemophagocytic lymphohistiocytosis), a patient with "cytokine storm" may have a declining ESR. This is thought to be due to the consumptive coagulopathy and decreased synthesis of fibrinogen, which seems to be a main driver in ESR [<a href="#rid78">78</a>].</p><p>Because numerous chronic factors can affect ESR, it is important to consider all the elements that influence ESR. It may be beneficial for clinicians to think of these confounders, more chronic conditions, which may give a "false positive" (or "false negative") value when considering and investigating a more acute condition (<a class="graphic graphic_table graphicRef141094" href="/d/graphic/141094.html" rel="external">table 1</a>). It should be noted that some diagnoses, such as heart failure, may chronically depress the ESR.</p><p class="headingAnchor" id="H11"><span class="h2">C-reactive protein</span><span class="headingEndMark"> — </span>Elevations of CRP occur in association with acute and chronic inflammation due to a range of causes, including infectious diseases and noninfectious inflammatory disorders. Modest increases in CRP levels, detected with highly sensitive assays, may also occur in association with metabolic stresses in the absence of acute or chronic inflammatory states as they have traditionally been viewed.</p><p class="headingAnchor" id="H85778911"><span class="h3">'Normal' CRP levels</span><span class="headingEndMark"> — </span>The level of CRP that is truly normal or clinically innocuous is not known. Data from a study conducted by the National Health and Nutrition Evaluation Survey of over 21,000 people in the United States revealed that CRP levels vary with age, sex, and race, with slightly higher levels seen with increased age, with female sex, and in African Americans (<a class="graphic graphic_table graphicRef59376" href="/d/graphic/59376.html" rel="external">table 2</a>) [<a href="#rid79">79</a>]. A rough correction of the CRP for age can be made by using the following formulas: the upper limit of the reference range (mg/dL) equals (age in years)/50 for men and (age in years/50) + 0.6 for women [<a href="#rid80">80,81</a>].</p><p>It is very important to note that there is no uniformity in the units that are used to report CRP levels. Some laboratories report CRP concentrations as mg/dL while others employ mg/L. Standard CRP determinations may be reported either in units of mg/dL or in units of mg/L, while determinations using a highly sensitive assay, generally referred to as "high-sensitivity CRP" (hs-CRP), are routinely reported in units of mg/L. (See <a class="local">'High-sensitivity CRP and low-grade inflammation'</a> below.)</p><p>Population studies reveal a skewed, rather than Gaussian, distribution of plasma CRP concentrations. About 70 to 90 percent of samples from reference populations have CRP concentrations under 0.3 mg/dL (3 mg/L), but some individuals have minor elevations up to 1 mg/dL (10 mg/L). What we commonly call normal ranges (properly called reference ranges) reported for CRP vary greatly from one laboratory to another, to a degree that cannot be explained on a biologic or technical basis. What is thus regarded as "elevated" is often misleading. It would be best to regard CRP concentrations &gt;1 mg/dL (10 mg/L) as indicating clinically significant inflammation while concentrations between 0.3 and 1 mg/dL (3 and 10 mg/L; minor CRP elevation) indicate what is commonly referred to as low-grade inflammation [<a href="#rid82">82</a>].</p><p>Low-grade inflammation is not accompanied by the classic signs of inflammation and may result from an immense number of metabolic stresses [<a href="#rid5">5,83-85</a>]. Some of these stresses are clinically apparent; examples include atherosclerosis, obesity, obstructive sleep apnea, insulin resistance, hypertension, and type 2 diabetes. Low-grade inflammation is, however, also associated with an astounding number of conditions and lifestyles known to be associated with poor health, including low levels of physical activity, prehypertension, a large variety of unhealthy diets, social isolation, and even being unmarried. This realization has led to a redefinition of inflammation as the innate immune response to harmful stimuli such as pathogens, injury, and metabolic stress [<a href="#rid86">86</a>].</p><p>Although CRP levels do not correlate with gestational age in pregnancy, median CRP levels are marginally higher during pregnancy when compared with nonpregnant persons [<a href="#rid87">87,88</a>]. Also, CRP levels increase during labor [<a href="#rid88">88</a>]. In addition to usual metabolic stressors, this low level of subclinical inflammation has been associated with preeclampsia and gestational diabetes [<a href="#rid89">89-91</a>].</p><p class="headingAnchor" id="H85778917"><span class="h3">Moderate to marked elevation of CRP</span><span class="headingEndMark"> — </span>In most inflammatory conditions, the CRP, like the ESR, becomes elevated as part of the acute phase response. Markedly elevated levels of CRP are strongly associated with infection. Infections, most often bacterial, were found in approximately 80 percent of patients with values in excess of 10 mg/dL (100 mg/L) and in 88 to 94 percent of patients with values over 50 mg/dL (500 mg/L) [<a href="#rid92">92,93</a>]. Levels of CRP may also be elevated in patients with viral infections, although usually not to the degree seen in patients with bacterial infection [<a href="#rid94">94,95</a>]. (See  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Serum biomarkers'</a>.)</p><p>ESR and CRP levels may be discrepant. This can occur due to differences in kinetics, with the CRP both rising and falling more rapidly than the ESR. It can also be related to characteristics of the inflammatory response and immune disease-related mechanisms; as an example, in systemic lupus erythematosus, substantial CRP elevations are typically not as common as elevations in the ESR, and the CRP generally does not rise, in relative terms, to as great a degree with increased disease activity as does the ESR [<a href="#rid96">96</a>]. (See <a class="local">'Discrepancies between acute phase reactant levels'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h3">High-sensitivity CRP and low-grade inflammation</span><span class="headingEndMark"> — </span>Some confusion has arisen because of widespread use of the terms "high-sensitivity CRP" and "low-grade inflammation" [<a href="#rid97">97</a>]. One common misunderstanding has been the incorrect belief that hs-CRP is different in some way from the CRP that has been measured for many years. It is not. "High-sensitivity" only means that the concentration of CRP was determined using an assay designed to measure and distinguish very low levels of CRP. The CRP that is measured is "plain old" CRP, it has no new or unique properties [<a href="#rid98">98</a>].</p><p>Minor CRP elevation (concentrations between 3 and 10 mg/L) is regarded as a marker of low-grade inflammation. Inflammation, one of the first responses of the activated innate immune system, has long been defined as the response to infection and tissue injury. Its presence was classically recognized by the presence of heat, swelling, redness, and pain. In the 21<sup>st</sup> century, our understanding of what can elicit inflammation has expanded considerably. We have learned that the innate immune system responds to metabolic stress with chronic low-grade inflammation ("metaflammation") without the classic signs of acute inflammation. This poorly defined state, sometimes referred to as mini-inflammation or subclinical inflammation, occurs in many conditions in which there are minor degrees of metabolic dysfunction, such as obesity and insulin resistance (see <a class="local">'C-reactive protein'</a> above). The low-grade inflammatory state differs in several important ways from the acute inflammation that occurs in response to infection or tissue injury [<a href="#rid97">97,99</a>]. The acute inflammatory state is associated with the classic signs of inflammation (swelling, erythema, warmth, and pain), while low-grade inflammation is not. Acute inflammation generally shows a marked CRP response while low-grade inflammation shows only minor CRP elevation. The inflammatory response to infection and tissue injury supports host defense, clearance of necrotic tissue, adaptation, and repair, while the purpose of low-grade inflammation appears to be restoration of metabolic homeostasis [<a href="#rid86">86,100</a>].</p><p>The factors that trigger the acute inflammatory response and low-grade inflammation differ as well. Acute inflammation is largely triggered by components of an invading pathogen, referred to as pathogen-associated molecular patterns (PAMPs), and by products of damaged cells, damage- (or danger-) associated molecular patterns (DAMPs) [<a href="#rid99">99</a>]. The latter are sometimes referred to as alarmins [<a href="#rid101">101</a>]. One molecular mechanism that can trigger low-grade inflammation and CRP induction in response to metabolic stress that has been well-studied is the unfolded protein response [<a href="#rid102">102</a>]. Just beginning to be investigated are other harmful metabolic stimuli that can trigger inflammatory responses ("metaflammation") via metabolism-associated molecular patterns (MAMPs) [<a href="#rid103">103</a>].</p><p>These differences between acute inflammation and low-grade inflammation are so great that two leading researchers in the field have suggested distinct nomenclatures for the latter; both "para-inflammation" and "metaflammation" (metabolically-triggered inflammation) have been proposed to emphasize the distinction between metabolic perturbation and inflammation as it is traditionally viewed, both of which may result in increases in CRP levels [<a href="#rid99">99,102</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Discrepancies between acute phase reactant levels</span><span class="headingEndMark"> — </span>Although elevations in multiple components of APR commonly occur together, not all happen uniformly in all patients. Discordance between concentrations of different APR is common; some may be elevated while others are not. Differences in the production of specific cytokines or their modulators in different diseases may account in large part for these variations [<a href="#rid2">2</a>]. Additionally, as a patient’s condition worsens or improves, the ESR changes relatively slowly, while CRP concentrations can change rapidly.</p><p>Discrepancies between ESR and CRP are found with some frequency. An elevated ESR observed together with a normal CRP is often a misleading result that may, for example, reflect the effects of blood constituents, such as monoclonal immunoglobulins, that are not related to inflammation but that can influence the ESR. It should not be routine practice to order serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP) in such instances, unless the clinical presentation suggests that a plasma cell dyscrasia may be present.</p><p>Systemic lupus erythematosus (SLE) represents an exception to the generalization that CRP concentrations correlate with the extent and severity of inflammation in patients with rheumatic disorders [<a href="#rid96">96</a>]. The ESR may be elevated, sometimes markedly, in patients with active SLE, while the CRP response is muted. The muted CRP response in SLE appears to result from the ability of type I interferons, which are highly expressed in most lupus patients, to inhibit CRP induction in hepatocytes [<a href="#rid104">104</a>]. While many patients with active SLE do not have significantly elevated CRP concentrations [<a href="#rid105">105</a>], CRP concentrations may be quite elevated in patients with active lupus serositis [<a href="#rid106">106</a>] or with chronic synovitis [<a href="#rid107">107</a>]. In a febrile lupus patient, marked CRP elevation (greater than 6 mg/dL) favors the diagnosis of bacterial infection [<a href="#rid105">105</a>]. In a landmark study, infection was present in all patients with CRP levels over 6 mg/dL (60 mg/L) except for those with serositis, supporting the clinical utility of regarding marked CRP elevation as strongly suggestive of infection [<a href="#rid106">106</a>]. (See  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a>.)</p><p>Another more common example reflects the acuity of the acute phase response. CRP levels measure a single molecule, and one will note acute and rapid rise and fall with an insult. By contrast, because ESR is the reflection of numerous factors and the interaction of these elements (ie, long half-life of some plasma proteins), ESR levels do not rapidly rise at the beginning of an inflammatory insult; similarly, normalization is slower. This difference between ESR and CRP can help clinicians distinguish between acute processes and a more chronic process (for example, high CRP and normal ESR may suggest an acute paronychia; by contrast, elevated CRP and ESR may suggest osteomyelitis).</p><p>In patients with active rheumatoid arthritis, the ESR and CRP generally tend to be parallel (ie, both are elevated or not elevated in a single patient). However, one study found that results for the two tests were discordant (ESR &gt;28 mm/hr with CRP ≤0.8 mg/dL or ESR ≤28 mm/hr with CRP &gt;0.8 mg/dL) in about one-quarter of patients with active rheumatoid arthritis in a large practice-based registry [<a href="#rid108">108</a>].</p><p>Several studies have suggested that elevations of the acute phase protein procalcitonin are highly specific for infection [<a href="#rid109">109-111</a>]; thus, procalcitonin may prove useful in differentiating infections from other inflammatory stimuli in autoimmune disease patients [<a href="#rid112">112-114</a>]. A 2012 systematic review and meta-analysis of nine observational studies that evaluated procalcitonin as a marker of infection in patients with autoimmune disease found that procalcitonin and CRP exhibited similar sensitivity for infection (75 versus 77 percent), but that procalcitonin had significantly higher specificity (90 versus 56 percent) [<a href="#rid115">115</a>]. Thus, procalcitonin determination was inadequate to exclude infection. Procalcitonin was found to be more sensitive and specific than CRP for the diagnosis or prognosis of sepsis by some investigators, while others have found no advantage of procalcitonin over CRP [<a href="#rid116">116</a>]. Further study is required to define its clinical utility in patients with systemic autoimmune disease. (See  <a class="medical medical_review" href="/d/html/6870.html" rel="external">"Acute bronchitis in adults", section on 'Procalcitonin'</a> and  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Serum biomarkers'</a>.)</p><p>Since there are undoubtedly a number of other clinical situations in which similar discrepancies occur, there probably is no single best laboratory test to reflect inflammation. The optimal use of acute phase protein measurements may be to obtain several measurements, usually ESR and CRP, rather than a single test [<a href="#rid108">108</a>]. The results must be interpreted in light of the clinical context and the considerations previously indicated.</p><p class="headingAnchor" id="H14"><span class="h1">SPECIFIC APPLICATIONS</span><span class="headingEndMark"> — </span>The assessment of acute phase reactants (APR) may be helpful in a range of disorders, where such testing may be useful for diagnosis, monitoring of disease activity, or as a prognostic marker, depending upon the condition. The appropriate use of APR testing is described separately in the topics on each condition or specific disorder. The following examples are conditions in which measurement of APR may be particularly helpful:</p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatoid arthritis – APR are helpful in monitoring disease activity in rheumatoid arthritis. Generally, both the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) respond to changes in disease activity and may be sensitive indicators. However, in one study, nearly 60 percent of patients with active rheumatoid arthritis had both ESR &lt;28 mm/h and CRP &lt;0.8 mg/dL, thereby limiting the utility of these APR for monitoring disease activity [<a href="#rid108">108</a>]. (See  <a class="medical medical_review" href="/d/html/7503.html" rel="external">"Biologic markers in the assessment of rheumatoid arthritis", section on 'Erythrocyte sedimentation rate'</a> and  <a class="medical medical_review" href="/d/html/7503.html" rel="external">"Biologic markers in the assessment of rheumatoid arthritis", section on 'C-reactive protein'</a>.)</p><p></p><p class="bulletIndent1">A multi-biomarker disease activity (MBDA) assay has been developed that measures a diverse variety of biomarkers, using these data to identify and estimate the level of disease activity in patients with rheumatoid arthritis and to predict disease progression. Molecules whose concentrations are measured include two acute phase proteins (CRP and serum amyloid A), as well as one or two each of the following: adhesion molecules, growth factors, cytokine-related proteins, matrix metalloproteinases, skeletal-related proteins, and hormones (see  <a class="medical medical_review" href="/d/html/7503.html" rel="external">"Biologic markers in the assessment of rheumatoid arthritis", section on 'Multi-protein biomarker algorithms'</a>). Because of leptins and other molecular markers that are affected by adiposity, MBDA scores are associated with obesity [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) – Both the ESR and CRP are useful in diagnosing PMR and GCA and usually correlate well with disease activity. (See  <a class="medical medical_review" href="/d/html/8222.html" rel="external">"Treatment of polymyalgia rheumatica"</a> and  <a class="medical medical_review" href="/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis"</a> and  <a class="medical medical_review" href="/d/html/8235.html" rel="external">"Clinical manifestations and diagnosis of polymyalgia rheumatica", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/d/html/8235.html" rel="external">"Clinical manifestations and diagnosis of polymyalgia rheumatica", section on 'Laboratory findings'</a> and  <a class="medical medical_review" href="/d/html/8235.html" rel="external">"Clinical manifestations and diagnosis of polymyalgia rheumatica", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis", section on 'When to suspect giant cell arteritis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus (SLE) – Comparison of the ESR and CRP may be useful in patients with SLE, particularly when infection is suspected. Discrepancies between the two APR are related to the particular nature of the immune response in these patients [<a href="#rid96">96</a>]. (See <a class="local">'Discrepancies between acute phase reactant levels'</a> above and  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Laboratory evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular disease – There is a continually expanding literature on the predictive value of CRP in cardiovascular disease and on the possible role of serum CRP in screening for cardiovascular risk. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1484.html" rel="external">"C-reactive protein in cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection – Infections are an important cause of elevated APR. Serial measurement may be used to assess response of chronic infections to treatment. As an example, the ESR and CRP fall when osteomyelitis is effectively treated. (See  <a class="medical medical_review" href="/d/html/7668.html" rel="external">"Nonvertebral osteomyelitis in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy – Measurements of APR may be helpful in assessing the prognosis in some patients with malignancy, assessing the presence or absence of tumor recurrence, and distinguishing a clonal from a reactive process. (See  <a class="medical medical_review" href="/d/html/6682.html" rel="external">"Approach to the patient with thrombocytosis"</a> and  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other chronic conditions – Indicators of inflammation imply a poor prognosis in many other conditions, including type II diabetes, peripheral vascular disease, uremia, and ischemic stroke. In older adults, elevated levels of APR predict "failure to thrive" and even increased mortality [<a href="#rid118">118</a>]. This may be because a minor acute phase response reflects the presence of some degree of ongoing metabolic perturbation which itself may contribute to a poor outcome. Alternatively, these minimally elevated acute phase protein levels may merely identify individuals who are biologically older and who have sustained a greater load of minor body insults and damage, such as would result from the cumulative effect of metabolic stress [<a href="#rid97">97,119</a>].</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – A change in the concentration of acute phase reactants (APR), defined as those proteins whose serum concentrations increase or decrease by at least 25 percent during inflammatory states, is a major pathophysiologic phenomenon that accompanies acute and chronic inflammation and tissue injury. Those proteins whose concentrations increase are commonly referred to as positive APR, while those whose concentrations decrease are regarded as negative APR. These changes are presumed to contribute to defensive or adaptive capabilities. (See <a class="local">'Introduction'</a> above and <a class="local">'Definition and regulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regulation</strong> – Changes in levels of APR result largely from the effects of cytokines, particularly interleukin (IL) 6, as well as IL-1 beta, tumor necrosis factor (TNF)-alpha, and interferon gamma. These proteins influence acute phase protein production in hepatocytes. (See <a class="local">'Definition and regulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functions</strong> – The assumption that APR are beneficial is based upon the known functions of the involved proteins and speculation as to how they may serve useful purposes in inflammation, healing, or adaptation to noxious stimuli. C-reactive protein (CRP) is a component of the innate immune response and seems to have both proinflammatory and antiinflammatory actions. A number of other APR can initiate or sustain inflammation, while some APR may be antiinflammatory. (See <a class="local">'Function'</a> above and <a class="local">'Roles of CRP'</a> above and <a class="local">'Roles of other proteins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ESR</strong> – The erythrocyte sedimentation rate (ESR), defined as the rate (mm/hour) at which erythrocytes suspended in plasma fall when placed in a vertical tube, reflects a variety of factors, most notably the plasma concentration of fibrinogen. Other constituents of the blood, such as immunoglobulins, can influence it as well. The ESR can also be affected by changes that may be unrelated to inflammation, including changes in erythrocyte size, shape, and number; and by other technical factors. (See <a class="local">'Erythrocyte sedimentation rate'</a> above and <a class="local">'Increased ESR'</a> above and <a class="local">'Decreased ESR'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CRP</strong> – The level of CRP that is truly normal or clinically innocuous is not known. The serum concentration in most people is under 3 mg/L. CRP levels vary somewhat with age, sex, and race. There is no uniformity in the units that are used to report CRP levels; some laboratories report CRP concentrations as mg/dL while others employ mg/L. Markedly elevated levels are strongly associated with infection. (See <a class="local">'C-reactive protein'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-level CRP elevations</strong> – Although CRP is a sensitive indicator of inflammation, it is not specific for our traditional concept of inflammation (tumor, calor, rubor, and dolor), especially at relatively low levels. Values between 0.3 and 1 mg/dL may reflect minor degrees of inflammation, such as that seen in periodontitis, but may also reflect low-grade inflammatory states in conditions in which there are minor degrees of metabolic dysfunction, such as obesity and insulin resistance. Values greater than 1 mg/dL (10 mg/L) are felt to reflect clinically significant inflammation. (See <a class="local">'C-reactive protein'</a> above and <a class="local">'High-sensitivity CRP and low-grade inflammation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discrepancies between ESR and CRP elevations</strong> – Although elevations in multiple components of the APR typically happen together, not all occur uniformly in all patients. Discordance between concentrations of different APR is common; discrepancies between ESR and CRP are found with some frequency. These variations may be partially explained by differences in the production of specific cytokines or their modulators in different diseases. (See <a class="local">'Discrepancies between acute phase reactant levels'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982; 389:39.</a></li><li><a class="nounderline abstract_t">Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448.</a></li><li><a class="nounderline abstract_t">Tillett WS, Francis T. SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS. J Exp Med 1930; 52:561.</a></li><li><a class="nounderline abstract_t">Kushner I, Samols D. Oswald Avery and the pneumococcus. Pharos Alpha Omega Alpha Honor Med Soc 2011; 74:14.</a></li><li><a class="nounderline abstract_t">Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med 2006; 119:166.e17.</a></li><li><a class="nounderline abstract_t">Bedell SE, Bush BT. Erythrocyte sedimentation rate. From folklore to facts. Am J Med 1985; 78:1001.</a></li><li><a class="nounderline abstract_t">Gauldie J, Richards C, Harnish D, et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987; 84:7251.</a></li><li><a class="nounderline abstract_t">Moshage HJ, Janssen JA, Franssen JH, et al. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987; 79:1635.</a></li><li><a class="nounderline abstract_t">Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997; 99:2930.</a></li><li><a class="nounderline abstract_t">Loyer P, Ilyin G, Abdel Razzak Z, et al. Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett 1993; 336:215.</a></li><li><a class="nounderline abstract_t">Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992; 149:2021.</a></li><li><a class="nounderline abstract_t">Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101:2461.</a></li><li><a class="nounderline abstract_t">Nijsten MW, Olinga P, The TH, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000; 28:458.</a></li><li><a class="nounderline abstract_t">Antonelli M, Kushner I. Low Serum Levels of 25-Hydroxyvitamin D Accompany Severe COVID-19 Because it is a Negative Acute Phase Reactant. Am J Med Sci 2021; 362:333.</a></li><li><a class="nounderline abstract_t">Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord 2017; 18:153.</a></li><li><a class="nounderline abstract_t">Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 2013; 45:256.</a></li><li><a class="nounderline abstract_t">Silva MC, Furlanetto TW. Does serum 25-hydroxyvitamin D decrease during acute-phase response? A systematic review. Nutr Res 2015; 35:91.</a></li><li><a class="nounderline abstract_t">Waldron JL, Ashby HL, Cornes MP, et al. Vitamin D: a negative acute phase reactant. J Clin Pathol 2013; 66:620.</a></li><li><a class="nounderline abstract_t">Reid D, Toole BJ, Knox S, et al. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin Nutr 2011; 93:1006.</a></li><li><a class="nounderline abstract_t">Krishnan A, Ochola J, Mundy J, et al. Acute fluid shifts influence the assessment of serum vitamin D status in critically ill patients. Crit Care 2010; 14:R216.</a></li><li><a class="nounderline abstract_t">Bertoldo F, Pancheri S, Zenari S, et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 2010; 25:447.</a></li><li><a class="nounderline abstract_t">Lordan R. Notable Developments for Vitamin D Amid the COVID-19 Pandemic, but Caution Warranted Overall: A Narrative Review. Nutrients 2021; 13.</a></li><li><a class="nounderline abstract_t">Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med 2019; 380:33.</a></li><li><a class="nounderline abstract_t">Kushner I. Semantics, inflammation, cytokines and common sense. Cytokine Growth Factor Rev 1998; 9:191.</a></li><li class="breakAll">Dinarello C. Cytokines as endogenous pyrogens. In: Fever: Basic mechanisms and management, Mackowiak P (Ed), Lippincott-Raven, Philadelphia 1997. p.87.</li><li><a class="nounderline abstract_t">Goldbach JM, Roth J, Zeisberger E. Fever suppression by subdiaphragmatic vagotomy in guinea pigs depends on the route of pyrogen administration. Am J Physiol 1997; 272:R675.</a></li><li><a class="nounderline abstract_t">Means RT. Hepcidin and cytokines in anaemia. Hematology 2004; 9:357.</a></li><li><a class="nounderline abstract_t">Sarraf P, Frederich RC, Turner EM, et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 1997; 185:171.</a></li><li class="breakAll">Krueger JM. Cytokine involvement in sleep responses to infection and physiological sleep. In: Cytokines in the Nervous System, Rothwell NJ (Ed), Landes Publishing, Austin 1996. p.41.</li><li><a class="nounderline abstract_t">Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351.</a></li><li><a class="nounderline abstract_t">Moldawer LL, Copeland EM 3rd. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer 1997; 79:1828.</a></li><li><a class="nounderline abstract_t">Wolf M, Böhm S, Brand M, Kreymann G. Proinflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 1996; 135:729.</a></li><li><a class="nounderline abstract_t">Li YP, Schwartz RJ, Waddell ID, et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 1998; 12:871.</a></li><li><a class="nounderline abstract_t">Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24:163.</a></li><li><a class="nounderline abstract_t">Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004; 279:48487.</a></li><li><a class="nounderline abstract_t">Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005; 117:104.</a></li><li><a class="nounderline abstract_t">Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38:189.</a></li><li><a class="nounderline abstract_t">Rhodes B, Fürnrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 2011; 7:282.</a></li><li><a class="nounderline abstract_t">Ahmed N, Thorley R, Xia D, et al. Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am J Respir Crit Care Med 1996; 153:1141.</a></li><li><a class="nounderline abstract_t">Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci U S A 1997; 94:2575.</a></li><li><a class="nounderline abstract_t">Jiang S, Xia D, Samols D. Expression of rabbit C-reactive protein in transgenic mice inhibits development of antigen-induced arthritis. Scand J Rheumatol 2006; 35:351.</a></li><li><a class="nounderline abstract_t">Zouki C, Beauchamp M, Baron C, Filep JG. Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 1997; 100:522.</a></li><li><a class="nounderline abstract_t">Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192:1353.</a></li><li><a class="nounderline abstract_t">Osmand AP, Friedenson B, Gewurz H, et al. Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A 1977; 74:739.</a></li><li><a class="nounderline abstract_t">Inforzato A, Bottazzi B, Garlanda C, et al. Pentraxins in humoral innate immunity. Adv Exp Med Biol 2012; 946:1.</a></li><li><a class="nounderline abstract_t">Daigo K, Inforzato A, Barajon I, et al. Pentraxins in the activation and regulation of innate immunity. Immunol Rev 2016; 274:202.</a></li><li><a class="nounderline abstract_t">Kapur R, Heitink-Pollé KM, Porcelijn L, et al. C-reactive protein enhances IgG-mediated phagocyte responses and thrombocytopenia. Blood 2015; 125:1793.</a></li><li><a class="nounderline abstract_t">Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4:361.</a></li><li><a class="nounderline abstract_t">Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82:513.</a></li><li><a class="nounderline abstract_t">Jones SA, Novick D, Horiuchi S, et al. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 1999; 189:599.</a></li><li><a class="nounderline abstract_t">Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190:1733.</a></li><li><a class="nounderline abstract_t">Tam SP, Flexman A, Hulme J, Kisilevsky R. Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J Lipid Res 2002; 43:1410.</a></li><li><a class="nounderline abstract_t">Kisilevsky R, Manley PN. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid 2012; 19:5.</a></li><li><a class="nounderline abstract_t">Su SB, Gong W, Gao JL, et al. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 1999; 189:395.</a></li><li><a class="nounderline abstract_t">Mullan RH, Bresnihan B, Golden-Mason L, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum 2006; 54:105.</a></li><li><a class="nounderline abstract_t">Boretti FS, Buehler PW, D'Agnillo F, et al. Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs. J Clin Invest 2009; 119:2271.</a></li><li><a class="nounderline abstract_t">Schaer DJ, Buehler PW, Alayash AI, et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013; 121:1276.</a></li><li><a class="nounderline abstract_t">Kilpatrick L, McCawley L, Nachiappan V, et al. Alpha-1-antichymotrypsin inhibits the NADPH oxidase-enzyme complex in phorbol ester-stimulated neutrophil membranes. J Immunol 1992; 149:3059.</a></li><li><a class="nounderline abstract_t">Cid MC, Grant DS, Hoffman GS, et al. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993; 91:977.</a></li><li><a class="nounderline abstract_t">Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996; 26:427.</a></li><li><a class="nounderline abstract_t">Fincher RM, Page MI. Clinical significance of extreme elevation of the erythrocyte sedimentation rate. Arch Intern Med 1986; 146:1581.</a></li><li><a class="nounderline abstract_t">Hayes GS, Stinson IN. Erythrocyte sedimentation rate and age. Arch Ophthalmol 1976; 94:939.</a></li><li><a class="nounderline abstract_t">Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed) 1983; 286:266.</a></li><li><a class="nounderline abstract_t">Ham TC, Curtis FC. Sedimentation rate of erythrocytes. Medicine (Baltimore) 1938; 17:447.</a></li><li><a class="nounderline abstract_t">Reinhart WH. [Erythrocyte sedimentation rate--more than an old fashion?]. Ther Umsch 2006; 63:108.</a></li><li><a class="nounderline abstract_t">van den Broe NR, Letsky EA. Pregnancy and the erythrocyte sedimentation rate. BJOG 2001; 108:1164.</a></li><li><a class="nounderline abstract_t">Bathon J, Graves J, Jens P, et al. The erythrocyte sedimentation rate in end-stage renal failure. Am J Kidney Dis 1987; 10:34.</a></li><li><a class="nounderline abstract_t">Shusterman N, Kimmel PL, Kiechle FL, et al. Factors influencing erythrocyte sedimentation in patients with chronic renal failure. Arch Intern Med 1985; 145:1796.</a></li><li><a class="nounderline abstract_t">Arik N, Bedir A, Günaydin M, et al. Do erythrocyte sedimentation rate and C-reactive protein levels have diagnostic usefulness in patients with renal failure? Nephron 2000; 86:224.</a></li><li><a class="nounderline abstract_t">Etminan A, Seyed Askari SM, Naghibzade Tahami A, et al. Relationship between the serum levels of Vitamin D and inflammatory markers in ESRD patients. Acta Biomed 2020; 91:e2020099.</a></li><li><a class="nounderline abstract_t">Liverman PC, Tucker FL, Bolton WK. Erythrocyte sedimentation rate in glomerular disease: association with urinary protein. Am J Nephrol 1988; 8:363.</a></li><li><a class="nounderline abstract_t">Leff RD, Akre SP. Obesity and the erythrocyte sedimentation rate. Ann Intern Med 1986; 105:143.</a></li><li><a class="nounderline abstract_t">Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19:972.</a></li><li><a class="nounderline abstract_t">Alende-Castro V, Alonso-Sampedro M, Vazquez-Temprano N, et al. Factors influencing erythrocyte sedimentation rate in adults: New evidence for an old test. Medicine (Baltimore) 2019; 98:e16816.</a></li><li><a class="nounderline abstract_t">Sox HC Jr, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Intern Med 1986; 104:515.</a></li><li><a class="nounderline abstract_t">Jurado RL. Why shouldn't we determine the erythrocyte sedimentation rate? Clin Infect Dis 2001; 33:548.</a></li><li><a class="nounderline abstract_t">Lawrence C, Fabry ME. Erythrocyte sedimentation rate during steady state and painful crisis in sickle cell anemia. Am J Med 1986; 81:801.</a></li><li><a class="nounderline abstract_t">Eloseily EMA, Minoia F, Crayne CB, et al. Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. ACR Open Rheumatol 2019; 1:345.</a></li><li><a class="nounderline abstract_t">Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005; 352:1611.</a></li><li><a class="nounderline abstract_t">Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol 2000; 27:2351.</a></li><li><a class="nounderline abstract_t">Ranganath VK, Elashoff DA, Khanna D, et al. Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. J Rheumatol 2005; 32:1040.</a></li><li><a class="nounderline abstract_t">Kushner I, Antonelli MJ. What should we regard as an "elevated" C-reactive protein level? Ann Intern Med 2015; 163:326.</a></li><li><a class="nounderline abstract_t">Slade GD, Ghezzi EM, Heiss G, et al. Relationship between periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk in Communities study. Arch Intern Med 2003; 163:1172.</a></li><li><a class="nounderline abstract_t">Giles JT, Bartlett SJ, Andersen R, et al. Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum 2008; 58:2632.</a></li><li><a class="nounderline abstract_t">Vuong J, Qiu Y, La M, et al. Reference intervals of complete blood count constituents are highly correlated to waist circumference: should obese patients have their own "normal values?". Am J Hematol 2014; 89:671.</a></li><li><a class="nounderline abstract_t">Antonelli M, Kushner I. It's time to redefine inflammation. FASEB J 2017; 31:1787.</a></li><li><a class="nounderline abstract_t">Belo L, Santos-Silva A, Rocha S, et al. Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur J Obstet Gynecol Reprod Biol 2005; 123:46.</a></li><li><a class="nounderline abstract_t">Watts DH, Krohn MA, Wener MH, Eschenbach DA. C-reactive protein in normal pregnancy. Obstet Gynecol 1991; 77:176.</a></li><li><a class="nounderline abstract_t">Gaillard R, Rifas-Shiman SL, Perng W, et al. Maternal inflammation during pregnancy and childhood adiposity. Obesity (Silver Spring) 2016; 24:1320.</a></li><li><a class="nounderline abstract_t">Leibowitz KL, Moore RH, Ahima RS, et al. Maternal obesity associated with inflammation in their children. World J Pediatr 2012; 8:76.</a></li><li><a class="nounderline abstract_t">Xiao R, Sorensen TK, Williams MA, Luthy DA. Influence of pre-eclampsia on fetal growth. J Matern Fetal Neonatal Med 2003; 13:157.</a></li><li><a class="nounderline abstract_t">Vanderschueren S, Deeren D, Knockaert DC, et al. Extremely elevated C-reactive protein. Eur J Intern Med 2006; 17:430.</a></li><li><a class="nounderline abstract_t">Le Gall C, Désidéri-Vaillant C, Nicolas X. [Significations of extremely elevated C-reactive protein: about 91 cases in a French hospital center]. Pathol Biol (Paris) 2011; 59:319.</a></li><li><a class="nounderline abstract_t">Krüger S, Ewig S, Papassotiriou J, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009; 10:65.</a></li><li><a class="nounderline abstract_t">Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206.</a></li><li><a class="nounderline abstract_t">Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008; 59:1814.</a></li><li><a class="nounderline abstract_t">Kushner I, Samols D, Magrey M. A unifying biologic explanation for "high-sensitivity" C-reactive protein and "low-grade" inflammation. Arthritis Care Res (Hoboken) 2010; 62:442.</a></li><li><a class="nounderline abstract_t">Casas JP, Shah T, Hingorani AD, et al. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008; 264:295.</a></li><li><a class="nounderline abstract_t">Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454:428.</a></li><li><a class="nounderline abstract_t">Chovatiya R, Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol Cell 2014; 54:281.</a></li><li><a class="nounderline abstract_t">Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81:1.</a></li><li><a class="nounderline abstract_t">Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860.</a></li><li><a class="nounderline abstract_t">Wang X, Wang Y, Antony V, et al. Metabolism-Associated Molecular Patterns (MAMPs). Trends Endocrinol Metab 2020; 31:712.</a></li><li><a class="nounderline abstract_t">Enocsson H, Sjöwall C, Skogh T, et al. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares? Arthritis Rheum 2009; 60:3755.</a></li><li><a class="nounderline abstract_t">Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982; 8:91.</a></li><li><a class="nounderline abstract_t">ter Borg EJ, Horst G, Limburg PC, et al. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990; 17:1642.</a></li><li><a class="nounderline abstract_t">Moutsopoulos HM, Mavridis AK, Acritidis NC, Avgerinos PC. High C-reactive protein response in lupus polyarthritis. Clin Exp Rheumatol 1983; 1:53.</a></li><li><a class="nounderline abstract_t">Kay J, Morgacheva O, Messing SP, et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 2014; 16:R40.</a></li><li><a class="nounderline abstract_t">Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 2011; 9:107.</a></li><li><a class="nounderline abstract_t">Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13:426.</a></li><li><a class="nounderline abstract_t">Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis 2012; 73:221.</a></li><li><a class="nounderline abstract_t">Tamaki K, Kogata Y, Sugiyama D, et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 2008; 35:114.</a></li><li><a class="nounderline abstract_t">Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40:1250.</a></li><li><a class="nounderline abstract_t">Brunkhorst R, Eberhardt OK, Haubitz M, Brunkhorst FM. Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection. Intensive Care Med 2000; 26 Suppl 2:S199.</a></li><li><a class="nounderline abstract_t">Wu JY, Lee SH, Shen CJ, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 2012; 64:3034.</a></li><li><a class="nounderline abstract_t">Samsudin I, Vasikaran SD. Clinical Utility and Measurement of Procalcitonin. Clin Biochem Rev 2017; 38:59.</a></li><li><a class="nounderline abstract_t">Curtis JR, Greenberg JD, Harrold LR, et al. Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. Semin Arthritis Rheum 2018; 47:472.</a></li><li><a class="nounderline abstract_t">Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106:506.</a></li><li><a class="nounderline abstract_t">Kushner I. C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging. Cleve Clin J Med 2001; 68:535.</a></li></ol></div><div id="topicVersionRevision">Topic 7483 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7046585" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The phenomenon of the acute phase response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9971870" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute-phase proteins and other systemic responses to inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19869788" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21615066" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Oswald Avery and the pneumococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443421" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : What does minor elevation of C-reactive protein signify?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4014259" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Erythrocyte sedimentation rate. From folklore to facts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2444978" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3584463" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9185517" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7505238" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381393" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12433676" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10708183" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34166653" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Low Serum Levels of 25-Hydroxyvitamin D Accompany Severe COVID-19 Because it is a Negative Acute Phase Reactant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28516265" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23238772" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Vitamin D in systemic and organ-specific autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631715" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Does serum 25-hydroxyvitamin D decrease during acute-phase response? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23454726" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Vitamin D: a negative acute phase reactant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21411617" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21110839" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Acute fluid shifts influence the assessment of serum vitamin D status in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20200999" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33652653" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Notable Developments for Vitamin D Amid the COVID-19 Pandemic, but Caution Warranted Overall: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415629" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9918118" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Semantics, inflammation, cytokines and common sense.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9918118" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Semantics, inflammation, cytokines and common sense.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9124494" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fever suppression by subdiaphragmatic vagotomy in guinea pigs depends on the route of pyrogen administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15763974" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hepcidin and cytokines in anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996253" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996253" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7715646" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129003" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9025720" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Proinflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9657527" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565523" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337754" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : C-reactive Protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214080" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : C-reactive protein: ligands, receptors and role in inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11532280" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Human C-reactive protein: expression, structure, and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21468143" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : C-reactive protein in rheumatology: biology and genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630558" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9122237" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062433" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Expression of rabbit C-reactive protein in transgenic mice inhibits development of antigen-induced arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9239398" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11067883" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/265538" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21948359" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pentraxins in humoral innate immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27782337" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pentraxins in the activation and regulation of innate immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25548320" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : C-reactive protein enhances IgG-mediated phagocyte responses and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1420997" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8329706" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9927522" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : C-reactive protein: a physiological activator of interleukin 6 receptor shedding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601349" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12235172" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22320226" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acute-phase serum amyloid A: perspectives on its physiological and pathological roles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892621" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16385502" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620788" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23264591" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1328390" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Alpha-1-antichymotrypsin inhibits the NADPH oxidase-enzyme complex in phorbol ester-stimulated neutrophil membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7680672" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8817153" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3729639" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical significance of extreme elevation of the erythrocyte sedimentation rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/938284" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Erythrocyte sedimentation rate and age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6402065" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Simple rule for calculating normal erythrocyte sedimentation rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sedimentation rate of erythrocytes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16450741" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : [Erythrocyte sedimentation rate--more than an old fashion?].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11762656" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pregnancy and the erythrocyte sedimentation rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605082" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The erythrocyte sedimentation rate in end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4037939" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Factors influencing erythrocyte sedimentation in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11015011" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Do erythrocyte sedimentation rate and C-reactive protein levels have diagnostic usefulness in patients with renal failure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33525284" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Relationship between the serum levels of Vitamin D and inflammatory markers in ESRD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3239598" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Erythrocyte sedimentation rate in glomerular disease: association with urinary protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3717798" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Obesity and the erythrocyte sedimentation rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10195925" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31441853" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Factors influencing erythrocyte sedimentation rate in adults: New evidence for an old test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3954279" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The erythrocyte sedimentation rate. Guidelines for rational use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11462193" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Why shouldn't we determine the erythrocyte sedimentation rate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3776987" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Erythrocyte sedimentation rate during steady state and painful crisis in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31777812" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15829550" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Distribution of C-reactive protein values in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11036829" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940764" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26280429" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : What should we regard as an "elevated" C-reactive protein level?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12767953" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Relationship between periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk in Communities study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759279" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Association of body fat with C-reactive protein in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24644218" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Reference intervals of complete blood count constituents are highly correlated to waist circumference: should obese patients have their own "normal values?".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28179421" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : It's time to redefine inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16260340" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1988876" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : C-reactive protein in normal pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27094573" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Maternal inflammation during pregnancy and childhood adiposity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21874618" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Maternal obesity associated with inflammation in their children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12820837" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Influence of pre-eclampsia on fetal growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16962952" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Extremely elevated C-reactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20483544" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : [Significations of extremely elevated C-reactive protein: about 91 cases in a French hospital center].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19594893" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307030" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035410" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : C-reactive protein and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20391496" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A unifying biologic explanation for "high-sensitivity" C-reactive protein and "low-grade" inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823504" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : C-reactive protein and coronary heart disease: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650913" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Origin and physiological roles of inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24766892" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Stress, inflammation, and defense of homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032697" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : DAMPs, PAMPs and alarmins: all we need to know about danger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17167474" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Inflammation and metabolic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32807598" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Metabolism-Associated Molecular Patterns (MAMPs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19950271" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6749401" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : C-reactive protein in SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2084238" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6681126" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : High C-reactive protein response in lupus polyarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24485007" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21936959" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375419" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704255" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18050369" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9214425" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18470720" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22605405" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29332972" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Clinical Utility and Measurement of Procalcitonin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28947312" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10335721" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11405614" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
